Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotigalimab in solid tumors
NCT02482168Phase 1Completed
- Sponsor
- Apexigen, Inc.
- Start
- May 2015
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of sotigalimab in solid tumor (3 arms), sponsored by Apexigen, Inc. Primary endpoints: Incidence of dose limiting toxicities at 28 days and Incidence of adverse events. Started May 2015; status: completed.
02
Drugs
sotigalimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02482168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02482168.